New guidelines will help doctors identify patients with a common memory-loss syndrome that is often misdiagnosed as Alzheimer's disease in older adults. The diagnostic criteria for limbic-predominant ...

The market expansion is further driven by the rising demand for innovative treatments addressing unmet medical needs in retinal care. As the understanding of retinal pathologies deepens ... emerging ...

Regeneron has scooped up Oxular, a retinal-disease-focused company based in the U.K., closing the deal at the very end of 2024. Word of the acquisition was first shared by Oxular’s former CEO ...

Sigma-2 receptor modulation using exogenous ligands reduces cellular damage associated with central nervous system degeneration in age-related pathologies such as Alzheimer’s disease, Parkinson’s ...

with greater amounts of viral proteins co-localized with tangles of phosphorylated tau -- one of the hallmarks of Alzheimer's disease pathology -- in brain regions especially vulnerable to ...

with greater amounts of viral proteins co-localized with tangles of phosphorylated tau—one of the hallmarks of Alzheimer's disease pathology—in brain regions especially vulnerable to Alzheimer ...

After years of stagnation in the search for a cure for Alzheimer’s — or at least breakthroughs — 2024 brought several exciting findings and confirmed others regarding the devastating dementing disease ...

A study from Washington University in St. Louis found taking suvorexant, a common insomnia medication, for two nights slightly decreased amyloid-beta and tau proteins linked to Alzheimer's.

The first pill to slow down the progression of Alzheimer’s disease is being studied for use on the NHS. Regulators are due to make a decision on the drug called hydromethylthionine mesylate ...

While nearly 7 million Americans aged 65 and older suffer from Alzheimer's disease, experts are reflecting on the advances in diagnosis, treatment and risk management that have been made in 2024.